Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Takeda Pharmaceutical : WFP and Takeda deepen partnership in West Africa to strengthen health emergency response

09/23/2021 | 03:22am EDT

A new JPY 1.3 billion (approximately USD 10.8 million) contribution from Takeda Pharmaceutical Company Limited (Takeda) Global CSR Program to the World Food Programme (WFP) builds on previous successes and brings forward a 5-year initiative to help strengthen regional health supply chain capacities in West Africa.

Takeda and WFP's existing partnership has focused on strengthening in-country public health supply chains and supporting long-term pandemic preparedness, combining Takeda's financial support with WFP's supply chain knowledge and experience, built over nearly six decades of working in some of the most logistically challenging environments in the world.

In West Africa, fragile supply chains can lead to delays and damage in the transport and storage of medicines and other vital health items, leaving vulnerable communities without the help they need. This new initiative, which will run from 2022 to 2026, will build on existing activities as part of the current Takeda-WFP partnership, helping to address supply chain gaps and challenges at a regional level, ensuring better accessibility and availability of health products in fragile environments through the WFP-managed United Nations Humanitarian Response Depot in Accra, Ghana.

The United Nations Humanitarian Response Depots (UNHRD) are a network of six strategically located hubs around the world that provide supply chain services to the humanitarian community. UNHRD Ghana, in Accra, supports humanitarian organizations working across17 West African countries. This initiative will enhance the capacity of UNHRD Accra to store and deliver temperature-sensitive health products on behalf of the humanitarian community, and will create a Regional Logistics Knowledge Centre, where supply chain professionals and representatives from national governments in the region can receive training on best-in-class supply chain practices, ensuring that they are better equipped to face and manage health emergencies.

"WFP has been working with Takeda since 2020 and we value this partnership enormously," said WFP's Executive Director David Beasley. "This new generous donation from Takeda reflects the success and sustainability of our collaboration and will help public and private actors in West Africa prepare for, and respond to, health emergencies -- so that vital supplies can reach those most in need."

"Takeda is proud to continue working with the World Food Programme to transform supply chains and ensure access to critical health products in West Africa," said Takako Ohyabu, Chief Global Corporate Affairs Officer at Takeda. "Our Global CSR Program partners are selected annually by our employees around the world. Through this program, we are focused on strengthening health systems and our work with WFP continues to be meaningful to employees. As we continue this partnership, we hope to empower communities in West Africa to be ready for the health challenges of the future."

Distributed by APO Group on behalf of World Food Programme (WFP).

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/27Health Care Stocks Slide Wednesday as Biotechs Weigh on Sector
MT
10/27Phathom Pharmaceuticals Stock Slumps Following Stock Offering Announcement
MT
10/27Takeda Pharmaceutical to Buy GammeDelta Therapeutics
MT
10/27Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic Cell ..
PU
10/27Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic &gamm..
BU
10/26Phathom Pharmaceuticals Launches 5 Million Share Offering
MT
10/21TAKEDA PHARMACEUTICAL : to Hold Second Quarter FY2021 Earnings Conference Calls
PU
10/20NOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10/20NOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 398 B 29 899 M 29 899 M
Net income 2022 249 B 2 188 M 2 188 M
Net Debt 2022 3 258 B 28 663 M 28 663 M
P/E ratio 2022 20,4x
Yield 2022 5,64%
Capitalization 5 018 B 44 093 M 44 153 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 191,00 JPY
Average target price 4 372,86 JPY
Spread / Average Target 37,0%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.02%44 093
JOHNSON & JOHNSON4.04%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.18.34%244 227
ELI LILLY AND COMPANY48.17%225 231